PRIMeD at Fred Hutch

Immuno-oncology research at Fred Hutch builds on decades of pioneering work in basic immunology and transplantation with the overarching goal of discovering curative therapies for all cancers. Built from a solid foundation of translational research in solid and hematologic malignancies, our group includes strong research programs in cell therapy (TCR/CAR) and transplant immunotherapy, and is expanding in tumor microenvironment, immune checkpoint & regulation, immunogenomics, and therapeutic vaccines, among others. 

Recent advancements in statistics, computational techniques and experimental technologies are transforming how we generate and analyze data. This big data has big potential. That potential can only be fully realized through collaboration between researchers with complementary skill sets, approaches, and resources. The Translational Data Science Integrated Research Center (TDS IRC) harnesses these advances and expertise to spur innovation and open new avenues for preventing and treating cancer and related diseases. The TDS IRC builds on recent data-based advances in the biomedical sciences, including technologies that are driving the generation of massive datasets, the exponential growth of publicly available data, and revolutionary approaches in statistics, machine learning and artificial intelligence that are changing data analysis.